Genmab — Juli 2012
-
det var det nemmeste
-
men nok ikke det klogeste
-
jeg tror nogen af profferne må begynde at kunne se ideen med Genmab
-
vi bombarderer ham med spørgsmål 16. august
-
det siger noget om markedet, når kursen ikke går gennem loftet
-
jeg mener de leverer varen, men den skal nok hedde 50% før folk virkeligt får øjnene op
-
mon ikke det er dette Carnegie har købt på?
-
de har garanteret set de WK data
-
det skal ikke runway på vores cash
I want a generator -
Uptake er faktisk lidt bedre end rituxian
-
salget voksede ligeså meget sidste kvartal som i de sidste 6 kvartaler (undtaget forrige) hvis det giver mening
-
jeg lader vær nu
det er bare så fortjent! -
However, we remain confident that our US business can return to sales growth in the future given
the potential contribution of the pipeline and recent performance of newly launched products such as Votrient
and Arzerra.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind